US Stock MarketDetailed Quotes
ANRO Alto Neuroscience
- 12.270
- -0.650-5.03%
Close May 28 15:59 ET
- 12.270
- 0.0000.00%
Post 16:00 ET
329.87MMarket Cap-7770P/E (TTM)
13.205High12.035Low133.66KVolume13.025Open12.920Pre Close1.67MTurnover1.45%Turnover RatioLossP/E (Static)26.88MShares24.00052wk High1.71P/B113.45MFloat Cap11.68052wk Low--Dividend TTM9.25MShs Float24.000Historical High--Div YieldTTM9.06%Amplitude11.680Historical Low12.460Avg Price1Lot Size
About Alto Neuroscience Company
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.
Company Profile
SymbolANRO
Company NameAlto Neuroscience
Listing DateFeb 2, 2024
Issue Price16.00
Founded2019
CEODr. Amit Etkin, M.D.
MarketNYSE
Employees63
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address369 South San Antonio Road
CityLos Altos
ProvinceCalifornia
CountryUnited States of America
Zip Code94022
Phone1-650-200-0412
Company Executives
- Name
- Position
- Salary
- Dr. Amit Etkin, M.D.
- President, Chief Executive Officer and Chairman of the Board
- 1.86M
- Nicholas Conrad Smith
- Chief Financial Officer
- 1.60M
- Michael Conick Hanley, Jr
- Chief Operating Officer
- --
- Adam Savitz
- Chief Medical Officer
- 1.24M
- Gwill York
- Independent Director
- 53.68K
- Christopher Nixon Cox
- Independent Director
- --
- Dr. Po Yu Chen
- Independent Director
- --
- Mahalakshmi Radhakrishnan
- Independent Director
- --
- Andrew Dreyfus
- Independent Director
- 107.37K
- Dr. Husseini Manji
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
